奥美沙坦对充血性心衰患者血循环中糖类抗原CA125和脑钠肽的干预(2)
总之,奥美沙坦治疗CHF 4周,能使患者血循环中CA125、BNP浓度显著降低,CA125、BNP可作为评价临床治疗CHF疗效的重要指标和可能机制之一。
参考文献
[1]Chen H H,Bumett J C.Natriuretic peptides in the pathophysiology of congestive heart failure[J].Curt Cardiol Rep,2002,2(2):198.
[2]胡大一.心脏病学实践:规范化治疗心力衰竭的预后评价[M].北京:人民卫生出版社,2002:102-107.
[3]Obrien T J,Tunimoto H,Konishi I,et al.More than 15 years of CA125:what is known about the antigen,its structure and its function[J].Int J Bid Markers,1998,13(4):188-195.
[4]Nagele H,Bahlo M,Klapdor R,et al.CAl25 and its relation to cardiac function[J].Am Heart J,1999,137(6):1044-1049.
[5]Mire D E, Silfani T N, Pugsley M K.A review of the structural and functional features of olmesartan medoxomil, an angiotensin receptor blocker[J].J Cardiovasc Pharmacol,2005,46(50):585-593.
[6]Rosendorff C,Atlas S A,Almendral J L.Angiotensin receptor blockade and cardiovascular hypertrophy results from the echocardiographic study of the effect on cardiovascular hypertrophy of olmesartan[J].J Hypertens,2006,24(Suppl.6):309.
(收稿日期:2013-03-28) (编辑:何玉勤), http://www.100md.com(杨仕强 易春)
参考文献
[1]Chen H H,Bumett J C.Natriuretic peptides in the pathophysiology of congestive heart failure[J].Curt Cardiol Rep,2002,2(2):198.
[2]胡大一.心脏病学实践:规范化治疗心力衰竭的预后评价[M].北京:人民卫生出版社,2002:102-107.
[3]Obrien T J,Tunimoto H,Konishi I,et al.More than 15 years of CA125:what is known about the antigen,its structure and its function[J].Int J Bid Markers,1998,13(4):188-195.
[4]Nagele H,Bahlo M,Klapdor R,et al.CAl25 and its relation to cardiac function[J].Am Heart J,1999,137(6):1044-1049.
[5]Mire D E, Silfani T N, Pugsley M K.A review of the structural and functional features of olmesartan medoxomil, an angiotensin receptor blocker[J].J Cardiovasc Pharmacol,2005,46(50):585-593.
[6]Rosendorff C,Atlas S A,Almendral J L.Angiotensin receptor blockade and cardiovascular hypertrophy results from the echocardiographic study of the effect on cardiovascular hypertrophy of olmesartan[J].J Hypertens,2006,24(Suppl.6):309.
(收稿日期:2013-03-28) (编辑:何玉勤), http://www.100md.com(杨仕强 易春)